Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

50425/245

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control num Complete if Known Substitute for form 1449/PTO Application Number 10/575,671 INFORMATION DISCLOSURE Filing Date July 25, 2008 STATEMENT BY APPLICANT First Named Inventor Bradley T. Messmer Art Unit 1642 (Use as many sheets as necessary) Examiner Name Sean E. Aeder

Attorney Docket Number

Sheet

1

2 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	A copy of the International Search Report for PCT Application No. PCT/US2004/033176.	
	2	A copy of the Written Opinion of the International Searching Authority for PCT Application No. PCT/US2004/033176.	
	3	A copy of the International Preliminary Report on Patentability for PCT Application No. PCT/US2004/033176.	
	4	A copy of the Office Action for European Application No. 04 794 503.5, dated February 2, 2010.	
	5	A copy of the Office Action for European Application No. 04 794 503.5, dated April 9, 2008.	
	6	VALETTO et al. "Chronic Lymphoid Leukemia." Bio. and Clin. Invest. III, Abstract #1784, p. 431a.	
	7	FAIS et al. "Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors." J. Clin. Invest. (1998), vol. 102, pp. 1515-25.	
	8	DAMLE et al. "Ig V Gene Mutation Status and CD38 Expression as Novel Prognostic Indicators in Chronic Lymphocytic Leukemia." Blood, Sept. 15, vol. 94, pp. 1840-47.	
	9	CHIORAZZI et al. "Immunoglobulin Variable Region Gene Characteristics and Surface Membrane Phenotype Define B-CLL Subgroups with Distinct Clinical Courses."	
		Chronic Lymphoid Leukemia, Marcel Dekker, New York, NY, US (2001) pp. 81-109.	

Examiner Date Considered

<sup>\*</sup>EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

considered, include copy of this form with next communication to applicate.

Applicant's usual cultiform designation matter (callound). Applicant is lead as shack mark next [English Impaging Tentation is statched.

1. Applicant's usual cultiform designation in the communication of Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SR/085 (07-09)

Approved for use through 07/31/2012, OMB 0651-0031 U.S. Parent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	er the Paperwork Red	uction Ad	t of 1995, no persons ar	e required to respond to a collection of information unless it contains a valid OMB control number  Complete if Known			
Substitut	e for form 1449/PTO			Application Number	10/575,671		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	July 25, 2008		
				First Named Inventor	Bradley T. Messmer		
	(Use as many she	ate ac n	araccan/i	Art Unit	1642		
	tose as many since	015 05 77	yy	Examiner Name	Sean E. Aeder		
Sheet	1	of	2	Attorney Docket Number	50425/245		

	NON PATENT LITERATURE DOCUMENTS			
Cite No.1				
10	GHIOTTO et al. "Remarkably Similar Antigen Receptors Among a Subset of Patients with Chronic Lymphocytic Leukemia." J. of Clin. Invest. Vol. 113:7, pp. 1008-1011.			
11	CARTER "Improving the Efficacy of Antibody-Based Cancer Therapies." Nature Reviews (2001) vol. 1, pp. 119-129.			
12	CHIORAZZI et al. "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from Studies of the B Cell Antigen Receptor." Annu. Rev. Immunol. 2005, 21:841-894.			
	10 11	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, act), cidale, page(s), volume-issue number(s), publisher, city and/or country where published.    GHIOTTO et al. "Remarkably Similar Antigen Receptors Among a Subset of Patients with Chronic Lymphocytic Leukemia." J. of Clin. Invest. Vol. 113-7, pp. 1008-1011.    CARTER "Improving the Efficacy of Antibody-Based Cancer Therapies." Nature Reviews (2001) vol. 1, pp. 119-129.    CHIORAZZI et al. "B Cell Chronic Lymphocytic Leukemia: Lessons Learned from		

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consistency missed copy of the form with next communication to applicate a check mark here if English Ingrugary Transition is statebuild. This collection of shormation is required by 37 CFR 1.8, The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confedentially is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including adjustment, preparent, and authorities the completed application form to the USPTO. There will very depending upon the unfolded case. Any comments on the application, and authorities the completed application form to the USPTO. There will very depending upon the unfolded case. Any comments on the Trademark Office, P.O. Box 1450, Alexandries, VA 22313-1466. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandries, VA 22313-1466. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: